Gilead Sciences, Inc. with ticker code (GILD) now have 28 confirmed analysts covering the stock with the consensus suggesting a rating of ‘buy’. The target price High/Low ranges between $125.00 and $69.00 and has a mean target at $96.76. Given that the stocks previous close was at $88.40 this indicates there is a potential upside of 9.5%. The 50 day MA is $86.87 and the 200 day MA is $74.90. The total market capitalization for the company now stands at 110.25B. The current share price for the company is: $88.46 USD
The potential market cap would be $120,668,255,227 based on the market consensus.
The company is not paying dividends at this time.
Other points of data to note are a P/E ratio of 982.89, revenue per share of $22.70 and a 11.96% return on assets.
Gilead Sciences, Inc. is a biopharmaceutical company. The Company is engaged in advancing medicines to prevent and treat life-threatening diseases, including human immunodeficiency virus (HIV), viral hepatitis and cancer. The Company offers products in HIV, Onocolgy, Liver Disease, Vekulaery, and Other. Under HIV, it offers Biktarvy, Complera/Eviplera, Genvoya, Odefsey, Stribild, and Truvada. Its Veklury (remdesivir) is a nucleotide analog RNA polymerase inhibitor indicated for the treatment of coronavirus disease 2019 (COVID-19). Under oncology it offers cell therapy containing Tecartus and Yescarta. Under this Liver Disease consists of Chronic hepatitis C virus (HCV) (Ledipasvir/Sofosbuvir and Sofosbuvir/Velpatasvir) and Chronic hepatitis B virus (HBV) / hepatitis delta virus (HDV) (Vemlidy and Viread). The Company’s other products include AmBisome and Letairis. It also operates a portfolio of small molecule inhibitors targeting PARP1 for oncology and MK2 for inflammatory diseases.
